Cytokinetics
CYTK
355 hedge funds and large institutions have $5.58B invested in Cytokinetics in 2025 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 140 increasing their positions, 110 reducing their positions, and 44 closing their positions.
302% more call options, than puts
Call options by funds: $184M | Put options by funds: $45.7M
27% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 110
25% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 44
3.79% more ownership
Funds ownership: 111.3% → 115.09% (+3.8%)
3% more funds holding
Funds holding: 346 → 355 (+9)
10% less capital invested
Capital invested by funds: $6.18B → $5.58B (-$608M)
20% less funds holding in top 10
Funds holding in top 10: 15 → 12 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$114M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$71.4M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$42.8M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$39.5M |
| 5 |
Jennison Associates
New York
|
+$31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$42.3M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$40M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$36.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$22M |
CYTK Hedge Fund Activity: Q1 2025 in Review
355 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2025, worth a combined $5.58B — down 9.8% from $6.18B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new CYTK positions and 44 closed out — a net gain of 11 holders — while 140 added to existing stakes and 110 trimmed.
The largest buyer was Bank of America, adding an estimated $114M. The largest seller was Logos Global Management, exiting entirely with an estimated $42.3M sold.
- 355 institutional investors held Cytokinetics (CYTK) as of Q1 2025, up from 346 in Q4 2024.
- Funds reported $5.58B of Cytokinetics stock for Q1 2025, down 9.8% quarter-over-quarter.
- 55 funds opened new Cytokinetics positions in Q1 2025 and 44 closed out, a net change of +11 holders.
- The largest Cytokinetics buyer in Q1 2025 was Bank of America, an estimated $114M added.
- The largest Cytokinetics seller in Q1 2025 was Logos Global Management, an estimated $42.3M sold.
Based on aggregated 13F filings for Q1 2025.